DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous
STADA Group takes a leading position in the third Barmer GEK discount
agreement round
10.09.2012 / 13:30
---------------------------------------------------------------------
Sales companies secure a total of 19 awards
Bad Vilbel, September 10, 2012 - The STADA Group's sales companies have
taken a leading position in the third tender for discount agreements with
Barmer GEK, the largest public health insurance organization in Germany.
They were able to secure twelve exclusive and seven multiple awards. The
total tender volume came to approximately EUR 382 million according to the
insurance. The contracts take effect in November 2012 and apply for 8.7
million insured persons.
'With this success, the STADA Group has once again proven its strong
position and efficiency in the challenging environment of German discount
agreements', says Hartmut Retzlaff, Chairman of the Executive Board. 'With
a view to the successful results of recent discount agreement rounds, we
are confident that we will be able to further expand our share of the
German generics market.'
Of the active pharmaceutical ingredients awarded to companies in the STADA
Group, ten are attributable to ALIUD PHARMA, eight to STADApharm and one to
a consortium bid from STADApharm and another manufacturer. One active
pharmaceutical ingredient is shared by STADApharm and ALIUD PHARMA in a
multiple award. Overall, the STADA Group was thereby awarded 18 active
ingredients including ibuprofen and dorzolamide.
About STADA Arzneimittel AG:
STADApharm GmbH and ALIUD PHARMA GmbH are sales companies of STADA
Arzneimittel AG. The Group is present in over 30 countries and has, among
other things, production facilities in Germany, Russia, Serbia, Vietnam and
China. In 2011, STADA Arzneimittel AG generated EUR 1.7 billion in sales
and had 7,867 employees worldwide as of June 30, 2012. In addition to
generics, STADA focuses on known branded products such as Grippostad,
Mobilat and Ladival.
Contact:
STADA Arzneimittel AG / Corporate Communications / StadastraÃe 2-18 /
D - 61118 Bad Vilbel /
Tel.: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-Mail:
communications@stada.de /
Or visit us in the Internet at www.stada.com.
End of Corporate News
---------------------------------------------------------------------
10.09.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime
Standard); Freiverkehr in Berlin, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
184739 10.09.2012
DGAP-News: STADA Group takes a leading position in the third Barmer GEK discount agreement round
| Source: EQS Group AG